Shanghai Shen Lian Biomedical Corp
SSE:688098
Shanghai Shen Lian Biomedical Corp
SSE:688098
Price:
8.42
CNY
1.57%
Market Closed
Market Cap:
¥3.5B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Shanghai Shen Lian Biomedical Corp
SSE:688098
|
CN |
|
Kuantum Papers Ltd
NSE:KUANTUM
|
IN |
|
Resource Alam Indonesia Tbk PT
IDX:KKGI
|
ID |
|
T
|
TAAL Enterprises Ltd
BSE:539956
|
IN |
|
A
|
Atos SE
XBER:AXI
|
FR |
|
A
|
aovo Touristik AG
XMUN:A8N
|
DE |
|
Senzime AB (publ)
STO:SEZI
|
SE |
|
Dolat Algotech Ltd
NSE:DOLATALGO
|
IN |
|
M
|
Maagh Advertising & Marketing Services Ltd
BSE:543624
|
IN |
|
Mach Natural Resources LP
NYSE:MNR
|
US |
|
Lendlease Global Commercial REIT
SGX:JYEU
|
SG |
|
Q
|
Qingmu Digital Technology Co Ltd
SZSE:301110
|
CN |
|
V
|
Victory Supermarket Chain Ltd
TASE:VCTR
|
IL |
|
D
|
Dong A Eltek Co Ltd
KOSDAQ:088130
|
KR |
|
Britannia Industries Ltd
BSE:500825
|
IN |
Relative Value
The Relative Value of one
Shanghai Shen Lian Biomedical Corp
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 8.42 CNY,
Shanghai Shen Lian Biomedical Corp
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Shanghai Shen Lian Biomedical Corp Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Shanghai Shen Lian Biomedical Corp Competitors
Shanghai Shen Lian Biomedical Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Shanghai Shen Lian Biomedical Corp
SSE:688098
|
3.5B CNY | 11.8 | -76 | -56.8 | -56.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
865.7B USD | 13.3 | 41.9 | 28.3 | 30.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
577.7B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.4B CHF | 4 | 19.3 | 11.4 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.4B USD | 4.5 | 16.2 | 10 | 12.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.2B GBP | 5 | 28.6 | 15.9 | 22.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.4B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.1B USD | 2.5 | 20 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.6B USD | 2.5 | 16.8 | 7.1 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
